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Abstract
Background: Delta opioid peptide [D-ala2,D-leU5]enkephalin (DADLE) induces hibernation in
summer ground squirrels, and enhances preservation and survival of isolated or transplanted lungs
and hearts. In the present study, we investigated the protective effect of DADLE in the central
nervous system.
Results: Adult Sprague-Dawley rats were pretreated with DADLE (4 mg/kg every 2 h × 4
injections, i.p.) or saline prior to unilateral occlusion of the middle cerebral artery (MCA). Daily
behavioral tests revealed that ischemic animals treated with DADLE did not show any significant
behavioral dysfunctions compared with saline-treated ischemic animals. Opioid antagonists only
transiently inhibited the protective effect of DADLE, indicating the participation of non-opioid
mechanisms in DADLE neuroprotection. Histological examination using triphenyltetrazolium
chloride (TTC) revealed that brains from ischemic animals treated with DADLE, either alone or
with adjuvant opioid blockers, exhibited almost completely intact striata. In contrast, brains from
ischemic animals that received saline showed significant infarction in the lateral striatum. Analyses
of apoptotic cell death revealed a significant increase in the p-53 mRNA expression in the striatum
of ischemic animals that received saline, while those that received DADLE exhibited near normal
striatal p-53 expression. This protective effect was accompanied by significant increments in
protein levels of glial cell line-derived neurotrophic factor in the striatum of DADLE-treated
ischemic animals.
Conclusion: These results indicate that DADLE protected against necrotic and apoptotic cell
death processes associated with ischemia-reperfusion injury. The present study demonstrates that
delta opioids are crucially involved in stroke, suggesting that the opioid system is important in the
study of brain injury and protection.

Background
Opioids have been well-documented as drugs of abuse [1]
and as potential analgesics [2]. Opioid receptors in tissues

and organs may mediate the drug activity, thus opioids
acting preferentially on mu, kappa or delta receptor alone
may produce unique behavioral and physiological
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responses. Delta opioids have been recently implicated in
ischemia [3-5]. Following occlusion of the middle cerebral artery in mice, delta binding sites were decreased at
least 6 h earlier than reductions in mu or kappa binding
sites, and concomitant with the extension of the infarct
core [3]. The early reduction in delta receptors prior to any
observable brain damage suggests that these receptors are
the class most sensitive to brain insults. Accordingly, stimulating the delta receptors may promote anti-ischemic
effects. A 'natural hibernation' condition has been suggested to achieve such anti-ischemic effects [4,5]. The
preservation of isolated rat hearts can be improved by
pharmacologically duplicating the common pathway to
natural hibernation and ischemic preconditioning, that is,
through an opening of the ATP-sensitive potassium channels [4]. Brain tissues collected from hibernating ground
squirrels were more tolerant to hypoxia and aglycemia
than those tissues from active squirrels [5]. These results
indicate that drugs that induce hibernation, such as [Dala2,D-leU5]enkephalin (DADLE), could act as antiischemic agents.
The commonality in the mechanisms (for example, oxidative stress, free radical formation) underlying the survival/
degeneration of tissues in the periphery and in the central
nervous system (CNS) suggests that DADLE may protect
against cerebral ischemia. In the present study, we examined this protective effect of DADLE in the CNS by pretreating young adult rats with this peptide and
subsequently exposing them to occlusion and reperfusion
surgery of the middle cerebral artery (MCAor). Routine
behavioral tests were employed to characterize functional
alterations during an acute post-ischemia period. The volume and size of infarction were analyzed using triphenyltetrazolium chloride (TTC) [6], a histological assay for
determining dehydrogenase activity. Because apoptotic
mechanism of cell death accompanies the MCA or stroke
model [7,8], we also investigated whether DADLE could
alter the expression of p-53 mRNA, which is an associated
marker for apoptosis. Finally, to elucidate possible opioid
receptor mediation of DADLE's functions in the CNS, we
carried out pharmacologic manipulations using delta opioid antagonists naltrexone (a universal opioid receptor
blocker) and naloxone methaiodide (a peripheral opioid
receptor blocker).

Results
DADLE attenuates motor asymmetrical behaviors
Daily behavioral tests revealed that ischemic animals
treated with DADLE displayed near normal behaviors
throughout the post-MCAor test period in a battery of
tests (Figure 1). In contrast, ischemic animals pretreated
with saline, naltrexone alone or naloxone methiodide
alone displayed significant abnormalities in elevated
body swing test (EBST), spontaneous rotational test, postural bias test, and forelimb akinesia test throughout the
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post-MCAor test period. The mean locomotor deficits in
these ischemic animals are as follows: 82.8% ± 12.3
(mean percentage biased swing response), 2.52 ± 0.56
(mean ipsiversive rotations per minute), 2.25 ± 0.31
(mean postural bias score), and 1.17 ± 0.15 (mean akinesia score). Ischemic animals pretreated with DADLE +
naloxone methiodide or DADLE + naltrexone also exhibited similar behavioral deficits at 24 h post-MCAor, but
showed near normal behaviors at 48 h and 72 h postMCAor. This observation of transient behavioral abnormalities in ischemic animals treated with DADLE + opioid
antagonists suggests that DADLE only partially exerted its
protection via the opioid system, and non-opioid mechanisms appear to mediate the majority of protective effects
of DADLE.
DADLE reduces cerebral infarction
TTC staining at 24 or 72 h after reperfusion revealed that
brains from ischemic animals that were treated with
DADLE, alone or with adjuvant opioid blockers, had
almost completely intact striata, whereas those from
ischemic animals that received saline showed significant
infarction in the lateral striatum (Figure 2A). Ischemic
animals pretreated with saline had a mean volume (±
S.E.M.) of 81.2 ± 5.3 mm3 of infarcted striatal tissue, while
ischemic animals pretreated with DADLE alone, DADLE +
naltrexone, or DADLE + naloxone methiodide had no
detectable infarction. Ischemic animals that received naltrexone alone or naloxone methiodide alone had a mean
volume of 78.7 ± 7.4 mm3 of striatal infarcted tissue,
which did not differ from the ischemic animals that
received saline alone. Analysis of variance (ANOVA)
revealed significant treatment effects (P < 0.0001) and post
hoc t-tests revealed significant reduction in infarct volume
in DADLE-treated ischemic animals, including those coadministered with opioid blockers, compared with salinetreated ischemic animals (P < 0.05). These histological
observations were consistent for both time periods of histological examination. The observation of almost intact
striatum following MCAor in DADLE-treated animals,
even with the co-administration of opioid antagonists,
suggests that DADLE protected against necrotic cell death
processes induced by ischemia-reperfusion injury.
DADLE decreases ischemia-induced apoptotic cell death
Analyses of apoptotic cell death revealed a significant
increment in the mRNA expression of p-53 in the striatum
of ischemic animals that received saline, while those that
received DADLE exhibited near normal striatal p-53
expression. ANOVA revealed a significant difference
across treatment conditions (F2,15 = 5.6, P < 0.05) (Figure
2B). Normalized values of p-53 mRNA expression showed
that vehicle-treated ischemic animals had a significant
increase in mRNA expression of p-53 in the ischemic striatum (65% increment) at 24 h post-MCAor surgery compared with the intact striatum of control, normal animals
Page 2 of 10
(page number not for citation purposes)

BMC Biology 2009, 7:31

http://www.biomedcentral.com/1741-7007/7/31

Figure 1
[D-ala2,D-leU5]enkephalin
(DADLE) attenuates ischemia-induced asymmetrical motor deficits
[D-ala2,D-leU5]enkephalin (DADLE) attenuates ischemia-induced asymmetrical motor deficits. Ischemic animals pretreated with saline (S), naltrexone alone (N) or naloxone methiodide alone (NM) displayed significant biased swing
activity (panel A), postural bias (panel B), spontaneous rotational behavior (panel C), and forelimb akinesia (panel D). In contrast, ischemic animals pretreated with DADLE + naltrexone (D + N) or DADLE + naloxone methiodide (D + NM) exhibited
significant dysfunctions in the same behavioral tests only at 0 to 24 h post occlusion and reperfusion surgery of the middle cerebral artery (MCAor) (days 0 and 1), and thereafter showed near normal behaviors at 48 h and 72 h post MCAor (days 2 and
3). In contrast, ischemic animals pretreated with DADLE alone (D) displayed near normal behaviors throughout the postMCAor test period.
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Figure
[D-ala2,D-leU5]enkephalin
2
(DADLE) reduces necrotic and apoptotic (panel B) cell death associated with ischemia
[D-ala2,D-leU5]enkephalin (DADLE) reduces necrotic and apoptotic (panel B) cell death associated with
ischemia. (A) Triphenyltetrazolium chloride (TTC) staining at 72 h post occlusion and reperfusion surgery of the middle cerebral artery (MCAor) revealed that the striata from ischemic animals exposed to ischemia/reperfusion surgery and pretreated
with saline showed dehydrogenase-deficient tissue (negative TTC stains). In contrast, the striata from ischemic animals pretreated with DADLE, DADLE + naloxone methiodide, or DADLE + naltrexone did not reveal any dehydrogenase deficiency.
(B) Ischemic animals exposed to ischemia/reperfusion injury and treated with saline showed a significant increase in mRNA
expression of p-53 in their ischemic striata (65% increment compared with intact striatum of normal, control animals) at 24 h
after stroke surgery. In contrast, ischemic animals treated with DADLE exhibited only a small increment in p-53 mRNA
expression in their ischemic striata at the same time period (28% increment compared with intact striatum of normal, control
animals; not significantly different from control values). Comparisons of ischemic striata between these two groups showed a
marked reduction in p-53 mRNA expression in DADLE-treated ischemic animals compared with saline-treated ischemic animals. (C) Immunohistochemical analyses of phenotypic markers of apoptosis revealed that DADLE significantly reduced caspase-3- (panels a, b, c, d) and Fas-positive cells (panels e, f, g, h) in DADLE-treated ischemic animals compared to saline-treated
ischemic animals. Quantitative data shown in bar graphs and represent means ± S.E.M. Asterisks correspond to statistical significance at P <0.05. To better capture the necrotic and apoptotic cells in saline-treated ischemic animals (panel d), higher magnification images are generated from propidium iodide (a) and caspase-3 (b) immunofluorescently labeled striatal cells,
respectively. Scale bar = 50 μm (a), 100 μm (b).
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(P < 0.01). In contrast, there was no significant difference
in p-53 mRNA expression between the ischemic striatum
(28% increment) of DADLE-treated ischemic animals and
the intact striatum of control, normal animals (P > 0.05).
Comparisons of ischemic striata showed a marked reduction (but only a trend, P = 0.07) in p-53 mRNA expression
in DADLE-treated ischemic animals compared with vehicle-treated ischemic animals. Moreover, immunohistochemical analyses of phenotypic markers of apoptosis
revealed significant reductions in caspase-3- and Fas-positive cells in DADLE-treated ischemic animals compared
with vehicle-treated ischemic animals (Figure 2C). These
results indicate that DADLE protected against apoptotic
cell death processes associated with ischemia-reperfusion
injury.
DADLE increases levels of glial cell line-derived
neurotrophic factor expression
Enzyme-linked immunosorbent assay (ELISA) examination of expression of neurotrophic factors revealed elevated levels of glial cell line-derived neurotrophic factor
(GDNF), but not nerve growth factor (NGF), in the striatal
and cortical tissues harvested from ischemic animals
treated with DADLE (Figure 3). Ischemic animals treated
with DADLE had significantly higher levels of GDNF compared with those treated with saline (P <0.05). However,
both groups did not differ in their levels of NGF (P >
0.05). These results indicate that DADLE specifically
increased GDNF, but not NGF.

http://www.biomedcentral.com/1741-7007/7/31

both ischemia-induced necrotic and apoptotic cell injury,
which could have promoted the observed behavioral protection.
The observation that DADLE exerts therapeutic effects in a
stroke model provides evidence for the need for further
investigating the role of the opioid system in cell degeneration and regeneration. The novelty of the present study is
the demonstration that a delta opioid agonist drug that
can induce hibernation protected the brain from ischemic
damage. The mu opioid, morphine, has been recently
shown to induce a Fas-mediated cell death [9]. Our data,
however, indicate that delta opioids possess protective
effects against cell death, for both necrotic and apoptotic
types. These results suggest that opioids, depending on the
specific receptor they trigger, can promote either degenerative or protective effects, in that mu opioids may promote neurotoxic effects [9], while kappa [10,11] and delta
opioids may produce protective/restorative effects.
The significant reductions in cerebral infarction and apoptotic cell death markers (p-53 mRNA expression, caspase3, and Fas) indicate that DADLE centrally promoted its
protective effects. We recently demonstrated that DADLE
blocks and even reverses the loss of dopamine transporters induced by chronic methamphetamine treatment
[12,13]. Moreover, DADLE inhibits accumulations of

Discussion
The present study demonstrated that DADLE protected
against MCA or ischemia-induced deficits. Animals that
were pretreated with DADLE and subsequently exposed to
the MCAor surgery did not show significant behavioral
deficits as revealed by a battery of tests, while ischemic
animals pretreated with saline alone exhibited significant
dysfunctions in all behavioral tests. Delta opioid blockers
naltrexone and naloxone methaiodide transiently antagonized the protective effects of DADLE at 24 h post MCAor
but not thereafter, indicating that DADLE's effects are only
partially mediated by opioid receptors. The data on TTC
staining (a marker of irreversible cell damage) revealed
almost no detectable dehydrogenase-deficient tissue
(necrotic infarction) in the striatum (the ischemic core) at
24 h or 72 h post MCAor in ischemic animals treated with
DADLE alone or DADLE + opioid blockers. Whereas opioid blockers transiently suppressed the behavioral protection by DADLE, they did not antagonize DADLE's
inhibition of ischemia-induced necrosis. In addition, striatal p-53 mRNA expression, an index of apoptosis, was
significantly suppressed by DADLE at 24 h post MCAor. In
contrast, an increment in striatal p-53 mRNA expression
was noted in ischemic animals that received saline alone.
Thus, pretreatment with DADLE was shown to rescue

tissues
glial
Figure
[D-ala2,D-leU5]enkephalin
cell 3line-derived neurotrophic
(DADLE)
factor
increases
(GDNF)
expression
in brain of
[D-ala2,D-leU5]enkephalin (DADLE) increases
expression of glial cell line-derived neurotrophic factor (GDNF) in brain tissues. Enzyme-linked immunosorbent assays (ELISA) revealed that the levels of GDNF proteins,
but not nerve growth factor (NGF), were significantly higher
in striatal and cortical tissues harvested from ischemic animals treated with DADLE compared with those treated with
saline. Data are expressed as mean percent of control ±
S.E.M. Asterisk indicates P <0.05. n = 6 samples for each neurotrophic factor examined.
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Figure 4 diagram summarizing timeline of experimental procedures in this study
Schematic
Schematic diagram summarizing timeline of experimental procedures in this study.
superoxide anions and hydroxyl radicals [14], which have
been shown as exacerbating factors for many neurological
disorders, including stroke [15,16]. The possibility exists
that ischemia-induced cell death involves the dopaminergic system, specifically the striatal dopamine pathway.
Indeed, we reported that many functional deficits associated with the MCAor are striatal dopamine-mediated
behaviors [17]. Animals with striatal ischemia display
methamphetamine-induced rotational behaviors [18], as
well as impairments in passive avoidance and Morris
water maze tests [19]. These findings implicate the
dopamine-rich innervated striatum as a critical brain area
for initiating neuroprotective strategies in this stroke
model.
The mechanism we proposed for the observed protective
effects of DADLE is the ability of DADLE to increase
expression of GDNF in the striatum and cortex, which are
the MCAor stroke target brain areas. We previously demonstrated that intracerebral infusion of GDNF protects
against cerebral ischemia [6]. Moreover, it has been established that GDNF is a highly selective dopamine neuron
survival agent [20,21]. We recently reported that DADLE
enhances embryonic dopamine cell viability in vitro and
following intrastriatal transplantation [22] and protects
adult dopaminergic neurons in vivo against 6-hydroxydopamine-induced neurotoxicity [23]. The present observation of increased GDNF striatal levels following DADLE
treatment suggests that the striatal dopaminergic system is
a highly potent target for DADLE in reversing ischemia
cell injury, as well as other diseases characterized by
dopamine dysfunctions.
The different onsets of behavioral recovery between
ischemic animals that received DADLE and those treated
with DADLE and opioid receptor blockers deserve clarification. DADLE-treated ischemic animals displayed significantly less behavioral deficits in the battery of tests
throughout the post-MCAor test period. In contrast, those

ischemic animals that received a combination of DADLE
and opioid receptor blockers did not exhibit improvements in stroke-induced behavioral deficits until 48 h,
which persisted up to 72 h post MCAor. This observation
of transient behavioral abnormalities in ischemic animals
treated with DADLE and opioid antagonists suggests that
DADLE only partially exerted its protection via the opioid
system, and non-opioid mechanisms appear to mediate
the majority of protective effects of DADLE. Accordingly,
blocking DADLE via the opioid pathway should only partially prevent DADLE's therapeutic benefits. The partial
antagonistic effects of opioid blockers were reflected in
the delayed onset of behavioral recovery in ischemic animals treated with DADLE and opioid blockers. The question arises then of why recovery could be initiated at a
later post-MCAor time point if these DADLE + opioid
blocker treated ischemic animals already exhibited behavioral deficits at early post-MCAor phase. Such delayed
functional recovery is likely explained by the temporal
profile of DADLE's non-opioid therapeutic action (that is,
GDNF upregulation). Based on the reported neurotrophic
effects of GDNF on endogenous cells [24,25], it is possible
that recruitment of newly formed cells from neurogenic
sites (that is, subventricular zone) towards the ischemic
striatal area was delayed, thereby corresponding to the
delayed behavioral recovery. Recent data from our laboratory indicate DADLE robust induction of neurogenesis
(data not shown).
The present behavioral and histological results parallel the
reported evolution of the penumbra during the acute phase
of ischemic stroke [26,27]. Stroke-induced histological alterations as revealed by TTC staining reveals that DADLEtreated ischemic animals, as well as those that received combined DADLE and opioid blockers, all demonstrate near
absent infarcts at 24 h post-stroke (that is, the earliest time
point we performed such infarct evaluation). Despite the
absence of massive infarcts, ischemic animals treated with
DADLE and opioid blockers initially exhibited significant
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behavioral deficits at 24 h, then their behaviors eventually
improved at 48 h and remained near normal levels at 72 h
post-stroke. Notwithstanding near normal gross histology,
the behavioral deficits at the very acute stage of stroke could
be due to subtle lesions and/or apoptotic cell death not
detected by TTC staining. The evolution of ischemic penumbra in these animals that initially demonstrated behavioral
deficits could have been similarly abrogated by DADLE's
non-opioid therapeutic action. It is likely that DADLE-mediated GDNF upregulation had already been in place even
prior to stroke, since DADLE was administered repeatedly
starting at 6 h pre-stroke. Our pre-stroke DADLE paradigm is
in agreement with previous studies reporting that optimal
GDNF therapeutic effects are achieved when initiated at an
ample time interval prior to injury [28,29]. DADLE neutrophic effects, even in those animals co-treated with opioid
blockers, could have been manifested in a two-pronged
approach. One pathway is to combat directly the ischemic
penumbra, and another process discussed above is via
recruitment of endogenous stem cells. The combination of
these two neuroprotective mechanisms was robust in
DADLE treated ischemic animals, while delayed (that is, 48
h) for those that received combined DADLE and opioid
blockers. Clearly, additional studies are warranted to reveal
the exact mechanism of action of DADLE, but our results
concur with prevailing concepts on stroke cell death cascades
and neuroprotective pathways.

Conclusion
The present study demonstrated that DADLE, possibly by
increasing GDNF expression in critical brain regions, prevented cell death processes and behavioral abnormalities
associated with experimental stroke in rats. The observation that a delta opioid peptide, previously shown to
induce hibernation, attenuated deficits inherent in cerebral ischemia provides a new pharmacological target for
stroke therapy.

Methods
Subjects
A total of 56 male Sprague-Dawley rats (Charles River, IN,
USA), weighing between 290 g and 330 g, served as subjects
in the present study. The animals were housed in a temperature-controlled room with normal 12–12 h light-dark
cycle. Food and water were freely available in the house
cage. All animal handling and surgical procedures adhered
to NIH IACUC guidelines. All investigators directly
involved in drug treatments, behavioral testing, and immunohistochemical analyses were blinded to the treatment
conditions. A schematic diagram is provided summarizing
experimental procedures in this study (Figure 4).
Treatment conditions
To establish the protective property of DADLE in the central nervous system, we pretreated young adult Sprague-
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Dawley rats with DADLE (4 mg/kg every 2 h × 4 injections, i.p.) or saline prior to unilateral MCAor. To elucidate the opioid mediation on the effects of DADLE, some
ischemic animals were treated with naltrexone (a universal opioid receptor blocker) or naloxone methiodide (a
peripheral opioid receptor blocker). Animals were randomly assigned to one treatment condition: DADLE alone
(n = 10), DADLE + naltrexone (n = 8), DADLE + naloxone
methiodide (n = 8), naloxone methiodide alone (n = 8),
naltrexone alone (n = 8), saline vehicle alone (n = 8), and
normal, no surgery/no treatment (n = 6). The present dosage of DADLE was within the reported efficacious range
for protection against loss of dopamine transporter
induced by chronic methamphetamine [13,14]. The dosages for naltrexone (0.1 mg/kg, i.p.) and naloxone methiodide (0.01 mg/kg, i.p.) were based on previous studies
showing each drug's maximal antagonistic effects [30,31].
Each delta opioid antagonist was injected simultaneously
with DADLE.
Ischemia surgery
Following the last drug injection, animals were subjected
to MCAor surgery. The surgical procedures were done
under aseptic conditions. Throughout the surgery and
until recovery, body temperature was kept at 37°C using
a thermal blanket connected to a rectal probe that controlled the heat delivery to the animal. In the present study,
we used the MCAor embolic technique as described elsewhere [17]. Under deep anesthesia using chloral hydrate
(400 mg/kg, i.p.), the right common carotid artery was
identified and isolated through a ventral midline cervical
incision. We used a suture filament with its tip coated
with a combination of dental substance mixture that
allows not only a smooth finish (avoiding artery perforations during insertion into the lumen) but more importantly a customized tip tapered to the desired gauge
depending on the animal weight, age, and gender. Such a
highly customized filament tip blocks the MCA better
than a flamed tip, allowing us to achieve better and consistent stroke and thus development of infarct within 1 h
faster than conventional flame-tapered filaments requiring 90 or 120 min of occlusion. Furthermore, TTC and
laser Doppler measurements revealed that our 1-h MCAo
produces infarct size and regional cerebral blood flow
reduction (>80%) comparable to that achieved by 90- or
120-min MCA occlusion. About 15 to 17 mm of the
suture filament was inserted from the junction of the
external and internal carotid arteries to block the MCA.
The right MCA was occluded for 1 h. Based on our own
studies and several others, a 1-h occlusion of the MCA
results in maximal infarction [17]. A major factor we highlight here that could have led to the present infarcts limited to the striatum is the use of liquid anesthesia, as
opposed to gas anesthesia. Since all animals received the
same anesthesia, any differences in stroke outcome
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parameters across could be ascribed to the experimental
drug.
Behavioral tests
After recovery from anesthesia, animals were evaluated on
a battery of tests including spontaneous rotational test,
EBST, postural bias test, and forelimb akinesia test. We
have reported that animals with successful MCA occlusion
exhibit asymmetric behaviors [17]. Ischemic animals have
been observed to rotate >2 full 360° ipsiversive turns,
swing = 75% towards the ischemic side, exhibit a postural
deficit characterized by a clipped (to the chest) left forelimb and stretched-out right forelimb, and display an akinetic left forelimb [17]. The EBST is described in detail
elsewhere [17], and has been utilized to characterize the
biased swing activity of ischemic animals starting at 1
month post-ischemia and extending up to 3 months postsurgery [17]. The animal was lifted 20 times by its tail and
the direction of the swing was recorded. An ipsiversive
swing activity of = 75% has been suggested as reflective of
successful unilateral ischemia or brain insult [17]. The
spontaneous rotational test [32] was performed immediately after the animal's recovery from anesthesia following
insertion of the embolus. The animal was placed in a
chamber made of transparent Plexiglas (40 × 40 × 35.5
cm3) and the direction of the animal's rotation was noted
over two 5-minute sessions. Two full turns (tight ipsiversive rotations) per minute was considered indicative of a
brain insult [17,32]. For the postural bias test and forelimb akinesia test, a semiquantitative scale was used as
described elsewhere [33]. The postural tail-hang test
involved holding the animal by the tail (similar to the
EBST) and noting the positions of the forelimbs. A scale is
used for grading the ischemic injury-induced dysfunctions
as follows: 0, rats extend straight both forelimbs. No
observable deficit; 1, rats keep the left forelimb to the
breast and extend straight the right forelimb; 2, rats show
decreased resistance to lateral push in addition to behavior in score 1 without circling; 3, rats twist the upper half
of their body in addition to behavior in score 2. Finally,
the forelimb akinesia test involved pulling each forelimb
at 90° away from the body median axis. The return of the
forelimb towards the midline was scored as 0 for slow
movement with rigidity, 1 for slow movement, and 2 for
smooth rapid movement. A score of 1 in the scale for postural bias test or forelimb akinesia test was considered as
indicative of CNS dysfunction [17]. These tests were used
to characterize any ameliorative effects of DADLE on
ischemia-induced dysfunctions from day 0 to day 3 after
MCAor surgery.
Cerebral infarction assay
The volume of infarction was analyzed using the TTC, a
histological assay for determining dehydrogenase activity.
Animals were euthanized at either 24 h or 72 h after
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MCAor surgery. Under deep anesthesia (chloral hydrate,
500 mg/kg, i.p.) animals were perfused intracardially with
saline. Details of the TTC procedure were described elsewhere [6]. The volume of infarction was measured in each
slice and summed using computerized planimetry (PCbased Image Tools software). The volume of infarction
was computed as: 2 mm (thickness of the slice) × [sum of
the infarction area in all brain slices (mm2)] [6]. To minimize artifacts produced by post-ischemic edema in the
infarcted area, the infarction area in the ipsilateral hemisphere was indirectly measured by subtracting the noninfarcted area in the ipsilateral hemisphere from the total
intact area of the contralateral hemisphere. An additional
cohort of ischemic animals (n = 4) underwent the same
treatment paradigm and were euthanized at 72 h poststroke for propidium iodide (P-3566, Molecular Probes,
Eugene, OR Eugene, OR, USA)Eugene, OR, 20 mg/kg via
tail vein) staining to further characterize necrotic cell
death.
p53 mRNA expression
To examine whether DADLE altered programmed cell
death or apoptosis, which has been postulated to mediate
ischemia-induced cell injury [7,8], we assayed for mRNA
expression of the apoptotic marker p53. At 24 h and 72 h
after MCAor surgery, randomly selected animals that
received either DADLE alone or saline alone were euthanized by rapid decapitation. The striatum was dissected
and quickly frozen using dry ice then stored in a -80°C
freezer until tissue processing was conducted. Total RNA
extraction, Northern blot analysis and hybridization followed those methods described elsewhere [34,35]. Analyses of resulting bands were quantified using a Macintosh
computer-based image analysis system (Image, NIH).
Densitometrically determined intensities of p-53 mRNA
were normalized to 18S rRNA.

In order to further characterize the effects of DADLE on
apoptotic cell death, 20 animals were subjected to the
same procedures as above, but we focused on only comparing DADLE (n = 10) against saline vehicle alone (n =
10). Rats were euthanized at 72 h after MCAor surgery.
The rats were perfused transcardially with 200 ml of cold
phosphate-buffered saline (PBS) and 200 ml of 4% paraformaldehyde in PBS. Brains were removed and post-fixed
in the same fixative overnight at 4°C with the subsequent
replacement with 30% sucrose in PBS for 72 h. The brains
were coronally sectioned at the thickness of 8 μm. Sections were washed 3 times for 5 min in PBS. Sections were
then incubated overnight at 4°C with caspase-3 (1:500,
Abcam, Cambridge, MA, USACambridge, MA Cambridge,
MA Cambridge, MA) or Fas (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA) primary antibody and
washed 3 times in PBS. Afterwards, sections were incubated with corresponding Cy3-conjugated secondary anti-
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bodies (1:1000, Jackson ImmunoResearch Lab, West
Grove, PA, USA) for 90 min. Finally sections were washed
3 times for 5 min each in distilled water, and coverslipped with Gelmount (Biomedia Corp., Foster City, CA,
USA). Control studies included exclusion of primary antibody substituted with 10% normal horse serum in PBS.
No immunoreactivity was observed in these controls. For
morphological analyses, immunoreactive cells in the
striatum within the ipsilateral to the stroke hemisphere
were examined using a Zeiss LSM510 confocal microscope (Oberkochen, Germany). Specifically, 6 coronal
sections at every 300 μm that approximately captured the
ischemic striatum (AP -2.0 to +2.0 mm from the bregma)
were examined from each rat and the number of positive
cells was counted in each 6 high power fields and the averages were used for the statistical analyses. Alternate sections from the additional cohort of animals used for
propidium iodide (see Cerebral infarction assay above)
were processed for caspase-3 immunofluorescent imaging
to further reveal apoptotic cell death.
Enzyme-linked immunosorbent assay
To examine possible non-opioid effects of DADLE, we
conducted assays of expression of neurotrophic factors
(GDNF and NGF) that have been previously shown to be
protective against ischemia [6,36]. Enzyme-linked immunosorbent assay (ELISA) was conducted on ischemic animals injected either with DADLE or with saline (n = 6 per
group). Following the same drug dosing regimen mentioned above, animals were rapidly decapitated, their
brains removed and striatal and frontal cortical tissues
quickly dissected. Brain homogenization and supernatant
acidification followed those methods described elsewhere
[37] with minor modifications. Protein concentrations
were measured by using the BCA Kit (Pierse, Rockford, IL,
USA). For the measurement of GDNF, mouse monoclonal
anti-GDNF antibody (R & D Systems, Inc., Minneapolis,
MN, USA) was used as a capture antibody and biotinylated goat anti-GDNF antibody (R & D Systems, Inc.,
Minneapolis, MN, USA) was used as a detection antibody.
For the measurement of NGF, the NGF Emax TM ImmunoAssay system (Promega Cooperation, Madison, WI,
USA) was used. The THERMOmax 96 well microplate
reader (Molecular Devices Corp., Sunnyvale, CA, USA)
was used to measure the optical densities.
Statistical analyses
ANOVA followed by post hoc test using Fisher's protected
least significant difference (PLSD) was used to reveal statistical significance in behavioral, mRNA, ELISA, and histological data. A statistically significant difference was preset at P <0.05.

Abbreviations
ANOVA: analysis of variance; CNS: central nervous system; DADLE: [D-ala2,D-leU5]enkephalin; EBST: elevated
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body swing test; ELISA: enzyme-linked immunosorbent
assay; GDNF: glial cell line-derived neurotrophic factor;
MCA: middle cerebral artery; MCAor: occlusion and reperfusion surgery of the middle cerebral artery; NGF: nerve
growth factor; PBS: phosphate-buffered saline; PLSD: protected least significant difference; TTC: triphenyltetrazolium.
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